HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed...
Hence then, the article about innocan pharma highlights breakthrough narrative review on liposomal synthetic cbd for chronic pain a novel non opioid analgesic approach was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach )
Also on site :
- Hollywood mourns loss of beloved makeup artist Jasen Kaplan
- Suspected mountain lion attack in Colorado mountains under investigation
- Person falls to death on Boylston Street on New Year’s Eve